PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2012-01-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT01443208
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Phase 2
Terminated
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Biological: PF-04856884
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01441414
- Locations
- 🇺🇸
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
🇺🇸Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Phase 1
Withdrawn
- Conditions
- Carcinoma, Renal CellGlioblastomaCarcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2011-12-20
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01441388
Patient's Management Receiving Eplerenone Therapy
Completed
- Conditions
- Left Ventricular Dysfunction Post Myocardial Infarction
- Interventions
- Other: Prospective Observational
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT01440049
Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 119
- Registration Number
- NCT01438957
- Locations
- 🇯🇵
Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan
🇯🇵Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵Kochi Medical School Hospital, Nangoku, Kochi, Japan
X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01438918
Impact Of RA Therapy Compliance On Patient-Reported Outcomes
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: biodmardsDrug: tDMARDs
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 396
- Registration Number
- NCT01438892
Food Effect Study For Apixaban Commercial Image Tablets
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT01437839
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT01436656
- Locations
- 🇨🇭
Universität Zürich, Zürich, Switzerland
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.
Phase 1
Completed
- Conditions
- MenopauseMetrorrhagiaPrimary Ovarian InsufficiencyVaginitis
- Interventions
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT01436513
- Locations
- 🇯🇵
Pfizer Investigational Site, Shinjyuku-ku, Tokyo, Japan